| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperlipoproteinemia Type II | 158 | 2021 | 375 | 42.430 |
Why?
|
| Lipoprotein(a) | 44 | 2021 | 435 | 10.840 |
Why?
|
| Dyslipidemias | 55 | 2021 | 851 | 10.070 |
Why?
|
| Cholesterol, LDL | 103 | 2021 | 2354 | 9.230 |
Why?
|
| Anticholesteremic Agents | 65 | 2021 | 979 | 9.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 101 | 2021 | 3255 | 8.060 |
Why?
|
| Hypolipidemic Agents | 47 | 2021 | 606 | 7.490 |
Why?
|
| Lipoproteins | 52 | 2020 | 881 | 5.440 |
Why?
|
| Hypertriglyceridemia | 16 | 2021 | 295 | 4.700 |
Why?
|
| Apolipoprotein B-100 | 34 | 2019 | 148 | 4.540 |
Why?
|
| Atherosclerosis | 48 | 2021 | 3445 | 4.440 |
Why?
|
| Cardiovascular Diseases | 96 | 2021 | 15142 | 4.260 |
Why?
|
| Apolipoproteins B | 41 | 2021 | 374 | 3.970 |
Why?
|
| Hyperlipidemias | 21 | 2021 | 789 | 3.370 |
Why?
|
| Blood Component Removal | 17 | 2020 | 125 | 3.350 |
Why?
|
| Triglycerides | 55 | 2021 | 2453 | 3.310 |
Why?
|
| Proprotein Convertases | 14 | 2018 | 95 | 3.280 |
Why?
|
| Cholesterol | 50 | 2021 | 2922 | 3.230 |
Why?
|
| Fenofibrate | 19 | 2018 | 89 | 3.050 |
Why?
|
| Postprandial Period | 15 | 2019 | 293 | 2.980 |
Why?
|
| Hypercholesterolemia | 20 | 2020 | 1151 | 2.930 |
Why?
|
| Coronary Artery Disease | 37 | 2021 | 6485 | 2.700 |
Why?
|
| Antibodies, Monoclonal | 25 | 2021 | 9272 | 2.640 |
Why?
|
| Australia | 42 | 2021 | 1167 | 2.640 |
Why?
|
| Lipid Metabolism | 26 | 2021 | 1885 | 2.620 |
Why?
|
| Genetic Testing | 29 | 2020 | 3439 | 2.580 |
Why?
|
| Lipoproteins, VLDL | 25 | 2018 | 201 | 2.470 |
Why?
|
| Receptors, LDL | 21 | 2020 | 477 | 2.460 |
Why?
|
| General Practice | 8 | 2021 | 100 | 2.390 |
Why?
|
| Apolipoprotein B-48 | 14 | 2018 | 20 | 2.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 46 | 2021 | 11729 | 2.220 |
Why?
|
| Cholesterol, HDL | 34 | 2021 | 1813 | 2.180 |
Why?
|
| Ubiquinone | 10 | 2018 | 188 | 2.120 |
Why?
|
| Apolipoprotein C-III | 19 | 2018 | 202 | 1.970 |
Why?
|
| Lipoproteins, LDL | 16 | 2019 | 642 | 1.960 |
Why?
|
| Mass Screening | 21 | 2020 | 5251 | 1.950 |
Why?
|
| Lipids | 32 | 2021 | 3307 | 1.790 |
Why?
|
| Diabetic Angiopathies | 10 | 2014 | 819 | 1.750 |
Why?
|
| Endothelium, Vascular | 27 | 2015 | 4459 | 1.730 |
Why?
|
| Fatty Acids, Omega-3 | 16 | 2019 | 1344 | 1.720 |
Why?
|
| Humans | 506 | 2021 | 743811 | 1.700 |
Why?
|
| Apolipoprotein A-II | 11 | 2016 | 39 | 1.690 |
Why?
|
| Fatty Liver | 9 | 2014 | 728 | 1.670 |
Why?
|
| Brachial Artery | 17 | 2018 | 369 | 1.650 |
Why?
|
| Serine Endopeptidases | 12 | 2015 | 1073 | 1.600 |
Why?
|
| Insulin Resistance | 34 | 2017 | 3863 | 1.510 |
Why?
|
| Risk Reduction Behavior | 10 | 2018 | 1125 | 1.490 |
Why?
|
| Lipoproteins, HDL | 20 | 2016 | 640 | 1.490 |
Why?
|
| Western Australia | 19 | 2020 | 41 | 1.450 |
Why?
|
| Primary Health Care | 11 | 2020 | 4556 | 1.430 |
Why?
|
| Cardiology | 8 | 2021 | 1668 | 1.360 |
Why?
|
| Coronary Disease | 18 | 2021 | 6078 | 1.340 |
Why?
|
| Dietary Supplements | 20 | 2019 | 3292 | 1.330 |
Why?
|
| Risk Factors | 111 | 2021 | 72252 | 1.290 |
Why?
|
| Hyperlipoproteinemias | 4 | 2019 | 20 | 1.280 |
Why?
|
| Apoprotein(a) | 4 | 2020 | 18 | 1.250 |
Why?
|
| Lipid Regulating Agents | 2 | 2019 | 24 | 1.220 |
Why?
|
| Intention | 3 | 2019 | 341 | 1.220 |
Why?
|
| Heptanoic Acids | 14 | 2015 | 343 | 1.180 |
Why?
|
| Early Diagnosis | 15 | 2018 | 1186 | 1.180 |
Why?
|
| General Practitioners | 5 | 2016 | 103 | 1.170 |
Why?
|
| Hyperlipidemia, Familial Combined | 2 | 2016 | 10 | 1.150 |
Why?
|
| Fluorobenzenes | 8 | 2015 | 183 | 1.150 |
Why?
|
| Kinetics | 39 | 2019 | 6476 | 1.140 |
Why?
|
| Apolipoprotein A-I | 16 | 2013 | 281 | 1.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2021 | 3921 | 1.110 |
Why?
|
| Middle Aged | 207 | 2021 | 213241 | 1.090 |
Why?
|
| Coronary Care Units | 3 | 2020 | 214 | 1.080 |
Why?
|
| Muscular Diseases | 5 | 2019 | 555 | 1.070 |
Why?
|
| Serine Proteinase Inhibitors | 4 | 2019 | 179 | 1.050 |
Why?
|
| Male | 244 | 2021 | 349776 | 1.040 |
Why?
|
| Obesity | 36 | 2020 | 12744 | 1.010 |
Why?
|
| Azetidines | 5 | 2015 | 142 | 1.000 |
Why?
|
| Eicosapentaenoic Acid | 8 | 2019 | 581 | 1.000 |
Why?
|
| Vasodilation | 13 | 2018 | 944 | 0.970 |
Why?
|
| Adiponectin | 11 | 2015 | 1101 | 0.960 |
Why?
|
| Blood Chemical Analysis | 6 | 2019 | 440 | 0.940 |
Why?
|
| Diet Therapy | 4 | 2019 | 154 | 0.930 |
Why?
|
| Forearm | 8 | 2010 | 409 | 0.920 |
Why?
|
| Adult | 162 | 2021 | 213889 | 0.910 |
Why?
|
| Oligonucleotides | 4 | 2021 | 572 | 0.890 |
Why?
|
| Arteries | 8 | 2011 | 1119 | 0.870 |
Why?
|
| Cost-Benefit Analysis | 15 | 2021 | 5388 | 0.860 |
Why?
|
| Pyrroles | 14 | 2015 | 1147 | 0.860 |
Why?
|
| Drug Therapy | 2 | 2016 | 496 | 0.850 |
Why?
|
| Carotid Artery Diseases | 6 | 2018 | 875 | 0.840 |
Why?
|
| Chylomicrons | 5 | 2010 | 26 | 0.830 |
Why?
|
| Consensus | 14 | 2020 | 2954 | 0.830 |
Why?
|
| Female | 189 | 2021 | 380020 | 0.830 |
Why?
|
| Self Care | 2 | 2018 | 786 | 0.820 |
Why?
|
| Diet, Reducing | 5 | 2014 | 462 | 0.810 |
Why?
|
| Polycystic Ovary Syndrome | 8 | 2014 | 370 | 0.800 |
Why?
|
| Cholesterol, VLDL | 9 | 2016 | 65 | 0.800 |
Why?
|
| Berberine | 2 | 2020 | 25 | 0.780 |
Why?
|
| International Cooperation | 5 | 2018 | 1419 | 0.770 |
Why?
|
| Dicarboxylic Acids | 1 | 2021 | 69 | 0.760 |
Why?
|
| Niacin | 5 | 2019 | 116 | 0.760 |
Why?
|
| Education, Medical, Continuing | 3 | 2018 | 840 | 0.760 |
Why?
|
| Disease Management | 5 | 2020 | 2459 | 0.760 |
Why?
|
| Delivery of Health Care | 6 | 2020 | 5319 | 0.760 |
Why?
|
| Isotope Labeling | 8 | 2014 | 405 | 0.750 |
Why?
|
| Obesity, Abdominal | 9 | 2016 | 359 | 0.750 |
Why?
|
| Nutritional Physiological Phenomena | 3 | 2008 | 370 | 0.750 |
Why?
|
| Renal Insufficiency, Chronic | 12 | 2019 | 2200 | 0.740 |
Why?
|
| Registries | 13 | 2020 | 8090 | 0.740 |
Why?
|
| Apolipoproteins A | 4 | 2019 | 94 | 0.730 |
Why?
|
| Internationality | 6 | 2019 | 1002 | 0.730 |
Why?
|
| Sulfonamides | 9 | 2015 | 1938 | 0.730 |
Why?
|
| Natural Killer T-Cells | 9 | 2019 | 316 | 0.730 |
Why?
|
| Medication Therapy Management | 2 | 2020 | 127 | 0.730 |
Why?
|
| Phenotype | 23 | 2021 | 16361 | 0.730 |
Why?
|
| Synovial Membrane | 9 | 2020 | 506 | 0.700 |
Why?
|
| Patient Care | 2 | 2017 | 638 | 0.700 |
Why?
|
| Aged | 109 | 2021 | 163178 | 0.690 |
Why?
|
| Carrier Proteins | 8 | 2016 | 5021 | 0.690 |
Why?
|
| Probucol | 5 | 2020 | 24 | 0.690 |
Why?
|
| Risk Assessment | 35 | 2020 | 23327 | 0.690 |
Why?
|
| Life Style | 11 | 2017 | 3833 | 0.680 |
Why?
|
| Peripheral Arterial Disease | 2 | 2020 | 1188 | 0.670 |
Why?
|
| Mutation | 28 | 2020 | 29777 | 0.660 |
Why?
|
| Blood Pressure | 22 | 2019 | 8551 | 0.660 |
Why?
|
| Liver | 19 | 2017 | 7479 | 0.650 |
Why?
|
| Family Health | 5 | 2016 | 1280 | 0.640 |
Why?
|
| Practice Guidelines as Topic | 16 | 2020 | 7270 | 0.630 |
Why?
|
| Double-Blind Method | 39 | 2021 | 12020 | 0.630 |
Why?
|
| Benzimidazoles | 4 | 2016 | 850 | 0.630 |
Why?
|
| Vasodilator Agents | 7 | 2015 | 974 | 0.630 |
Why?
|
| Fatty Acids, Nonesterified | 7 | 2016 | 402 | 0.630 |
Why?
|
| Fatty Acids | 6 | 2021 | 1809 | 0.620 |
Why?
|
| Drug Therapy, Combination | 21 | 2019 | 6487 | 0.620 |
Why?
|
| Genetic Predisposition to Disease | 24 | 2021 | 17439 | 0.610 |
Why?
|
| Physicians, Primary Care | 3 | 2021 | 592 | 0.610 |
Why?
|
| Vascular Diseases | 5 | 2016 | 1161 | 0.610 |
Why?
|
| Fibroblasts | 12 | 2020 | 4162 | 0.600 |
Why?
|
| Models, Biological | 16 | 2017 | 9582 | 0.600 |
Why?
|
| Plaque, Atherosclerotic | 6 | 2020 | 1518 | 0.600 |
Why?
|
| Diet | 13 | 2017 | 7930 | 0.590 |
Why?
|
| Psychotic Disorders | 12 | 2020 | 3044 | 0.580 |
Why?
|
| Cholestyramine Resin | 1 | 2016 | 24 | 0.580 |
Why?
|
| Carotid Arteries | 5 | 2018 | 949 | 0.570 |
Why?
|
| Pyrimidines | 8 | 2015 | 2945 | 0.560 |
Why?
|
| Clinical Trials as Topic | 12 | 2019 | 7908 | 0.550 |
Why?
|
| Prevalence | 25 | 2021 | 15211 | 0.530 |
Why?
|
| Preventive Health Services | 2 | 2019 | 575 | 0.530 |
Why?
|
| Adolescent | 47 | 2021 | 85729 | 0.520 |
Why?
|
| Abetalipoproteinemia | 1 | 2015 | 17 | 0.520 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 214 | 0.520 |
Why?
|
| Telomere | 2 | 2018 | 910 | 0.510 |
Why?
|
| Predictive Value of Tests | 25 | 2021 | 15067 | 0.510 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2019 | 588 | 0.500 |
Why?
|
| Homeostasis | 12 | 2017 | 3337 | 0.500 |
Why?
|
| Niemann-Pick Disease, Type B | 1 | 2014 | 7 | 0.490 |
Why?
|
| Homozygote | 11 | 2019 | 1787 | 0.490 |
Why?
|
| Models, Cardiovascular | 1 | 2019 | 996 | 0.480 |
Why?
|
| Heterozygote | 14 | 2019 | 2803 | 0.480 |
Why?
|
| Treatment Outcome | 50 | 2021 | 63042 | 0.480 |
Why?
|
| Medication Adherence | 5 | 2021 | 2063 | 0.480 |
Why?
|
| Cross-Over Studies | 19 | 2018 | 2029 | 0.470 |
Why?
|
| Young Adult | 41 | 2020 | 56392 | 0.470 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2014 | 64 | 0.470 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2014 | 91 | 0.460 |
Why?
|
| Acute Coronary Syndrome | 3 | 2017 | 2337 | 0.460 |
Why?
|
| Foundations | 1 | 2013 | 94 | 0.460 |
Why?
|
| Hypertension | 13 | 2021 | 8480 | 0.460 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 12 | 2015 | 361 | 0.460 |
Why?
|
| Adipose Tissue | 9 | 2015 | 3280 | 0.450 |
Why?
|
| Forecasting | 4 | 2018 | 2950 | 0.450 |
Why?
|
| Glucagon-Like Peptide 2 | 1 | 2013 | 50 | 0.450 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2018 | 941 | 0.450 |
Why?
|
| Animals | 62 | 2020 | 168660 | 0.440 |
Why?
|
| Fasting | 5 | 2016 | 1590 | 0.440 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 2013 | 122 | 0.440 |
Why?
|
| Steroid Metabolism, Inborn Errors | 1 | 2012 | 2 | 0.440 |
Why?
|
| Immunization | 1 | 2017 | 1255 | 0.430 |
Why?
|
| Health Literacy | 1 | 2018 | 414 | 0.430 |
Why?
|
| Models, Theoretical | 2 | 2016 | 3587 | 0.430 |
Why?
|
| Arthritis, Rheumatoid | 11 | 2020 | 3712 | 0.430 |
Why?
|
| Cross-Sectional Studies | 25 | 2021 | 25032 | 0.430 |
Why?
|
| Cholinergic Antagonists | 1 | 2013 | 165 | 0.420 |
Why?
|
| Hepatocytes | 2 | 2017 | 1211 | 0.420 |
Why?
|
| Weight Loss | 9 | 2014 | 2625 | 0.420 |
Why?
|
| Apolipoproteins | 8 | 2014 | 317 | 0.420 |
Why?
|
| DNA Mutational Analysis | 7 | 2019 | 4183 | 0.420 |
Why?
|
| Malaysia | 4 | 2021 | 92 | 0.400 |
Why?
|
| Secondary Prevention | 6 | 2021 | 1529 | 0.390 |
Why?
|
| Simvastatin | 2 | 2015 | 360 | 0.390 |
Why?
|
| Vascular Resistance | 6 | 2016 | 936 | 0.390 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 1476 | 0.380 |
Why?
|
| Cadherins | 5 | 2019 | 907 | 0.380 |
Why?
|
| Coronary Stenosis | 2 | 2018 | 833 | 0.380 |
Why?
|
| Safety | 1 | 2016 | 1184 | 0.380 |
Why?
|
| Herpesvirus 2, Human | 1 | 2012 | 189 | 0.380 |
Why?
|
| Child | 30 | 2021 | 77637 | 0.370 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2013 | 340 | 0.370 |
Why?
|
| Diet, Fat-Restricted | 3 | 2010 | 320 | 0.370 |
Why?
|
| Australasia | 4 | 2017 | 19 | 0.370 |
Why?
|
| Diabetes Complications | 2 | 2020 | 1360 | 0.370 |
Why?
|
| Pravastatin | 3 | 2017 | 395 | 0.370 |
Why?
|
| Phytosterols | 5 | 2010 | 65 | 0.360 |
Why?
|
| Patient Participation | 1 | 2019 | 1457 | 0.360 |
Why?
|
| Morbidity | 4 | 2020 | 1768 | 0.360 |
Why?
|
| Genotype | 7 | 2020 | 12944 | 0.360 |
Why?
|
| Docosahexaenoic Acids | 6 | 2016 | 877 | 0.360 |
Why?
|
| Pharmacists | 1 | 2012 | 248 | 0.360 |
Why?
|
| Physicians | 2 | 2021 | 4569 | 0.350 |
Why?
|
| Benzodiazepines | 1 | 2016 | 1101 | 0.350 |
Why?
|
| Sterol O-Acyltransferase | 1 | 2009 | 27 | 0.350 |
Why?
|
| Cost of Illness | 4 | 2020 | 1859 | 0.350 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 1438 | 0.340 |
Why?
|
| Renal Insufficiency | 1 | 2015 | 805 | 0.340 |
Why?
|
| Genetic Markers | 5 | 2018 | 2634 | 0.340 |
Why?
|
| Professional Role | 1 | 2012 | 306 | 0.340 |
Why?
|
| Energy Metabolism | 2 | 2020 | 2899 | 0.340 |
Why?
|
| Phospholipid Transfer Proteins | 2 | 2006 | 91 | 0.330 |
Why?
|
| Standard of Care | 1 | 2012 | 564 | 0.330 |
Why?
|
| Herpes Simplex | 1 | 2012 | 470 | 0.330 |
Why?
|
| Endothelium | 1 | 2011 | 777 | 0.320 |
Why?
|
| Capsules | 3 | 2020 | 196 | 0.320 |
Why?
|
| Vulnerable Populations | 1 | 2014 | 685 | 0.320 |
Why?
|
| Muscle, Skeletal | 3 | 2019 | 4925 | 0.320 |
Why?
|
| Oxidative Stress | 5 | 2016 | 3082 | 0.320 |
Why?
|
| Combined Modality Therapy | 8 | 2020 | 8637 | 0.320 |
Why?
|
| Pedigree | 9 | 2019 | 4643 | 0.320 |
Why?
|
| Blood Glucose | 14 | 2020 | 6259 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 17 | 2020 | 9944 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2019 | 3338 | 0.310 |
Why?
|
| Incidence | 9 | 2020 | 20948 | 0.310 |
Why?
|
| Metabolism | 2 | 2015 | 196 | 0.310 |
Why?
|
| Gemfibrozil | 1 | 2007 | 30 | 0.310 |
Why?
|
| Starvation | 1 | 2008 | 134 | 0.300 |
Why?
|
| Patient Discharge | 1 | 2020 | 3317 | 0.300 |
Why?
|
| Impotence, Vasculogenic | 1 | 2007 | 11 | 0.300 |
Why?
|
| Congenital Abnormalities | 1 | 2012 | 707 | 0.300 |
Why?
|
| Algorithms | 7 | 2019 | 13869 | 0.300 |
Why?
|
| Patient Admission | 1 | 2015 | 1380 | 0.300 |
Why?
|
| Lipid Metabolism Disorders | 2 | 2020 | 19 | 0.300 |
Why?
|
| Myocardial Infarction | 6 | 2021 | 11708 | 0.300 |
Why?
|
| Hypoglycemic Agents | 6 | 2020 | 2877 | 0.300 |
Why?
|
| Fibric Acids | 3 | 2017 | 25 | 0.300 |
Why?
|
| Parents | 2 | 2018 | 3403 | 0.300 |
Why?
|
| Pancreatitis | 1 | 2014 | 1092 | 0.300 |
Why?
|
| Prognosis | 17 | 2021 | 29052 | 0.290 |
Why?
|
| Lipolysis | 1 | 2008 | 210 | 0.290 |
Why?
|
| Regional Blood Flow | 8 | 2010 | 1525 | 0.290 |
Why?
|
| Arteriosclerosis | 4 | 2005 | 1092 | 0.290 |
Why?
|
| Kidney Failure, Chronic | 3 | 2011 | 2534 | 0.280 |
Why?
|
| Antigens, CD1d | 4 | 2017 | 220 | 0.280 |
Why?
|
| Stroke | 5 | 2021 | 9975 | 0.280 |
Why?
|
| Sodium Fluoride | 3 | 2021 | 66 | 0.270 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2007 | 211 | 0.270 |
Why?
|
| Mutation, Missense | 2 | 2014 | 2566 | 0.270 |
Why?
|
| Gastrectomy | 1 | 2010 | 663 | 0.270 |
Why?
|
| Taiwan | 2 | 2019 | 497 | 0.270 |
Why?
|
| Age Factors | 10 | 2020 | 18355 | 0.270 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 4 | 2018 | 226 | 0.270 |
Why?
|
| Leucine | 8 | 2014 | 559 | 0.270 |
Why?
|
| Regression Analysis | 13 | 2016 | 6457 | 0.270 |
Why?
|
| Intestines | 3 | 2013 | 1923 | 0.270 |
Why?
|
| Drug Delivery Systems | 3 | 2020 | 2217 | 0.260 |
Why?
|
| Ultrasonography | 9 | 2018 | 5986 | 0.260 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3134 | 0.260 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2021 | 432 | 0.260 |
Why?
|
| Insulin | 13 | 2015 | 6584 | 0.260 |
Why?
|
| Preventive Medicine | 1 | 2007 | 263 | 0.260 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3241 | 0.260 |
Why?
|
| Nephrotic Syndrome | 3 | 2007 | 389 | 0.260 |
Why?
|
| Bile Acids and Salts | 2 | 2020 | 368 | 0.260 |
Why?
|
| Biological Transport | 6 | 2015 | 2119 | 0.260 |
Why?
|
| Phospholipids | 4 | 2014 | 784 | 0.260 |
Why?
|
| PPAR alpha | 2 | 2019 | 198 | 0.250 |
Why?
|
| Nitric Oxide Synthase | 2 | 2007 | 915 | 0.250 |
Why?
|
| Brazil | 2 | 2019 | 1264 | 0.250 |
Why?
|
| China | 4 | 2019 | 2243 | 0.250 |
Why?
|
| Dietary Fats | 4 | 2018 | 2016 | 0.250 |
Why?
|
| Apolipoproteins C | 6 | 2011 | 59 | 0.250 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2020 | 738 | 0.240 |
Why?
|
| Platelet Activation | 3 | 2018 | 674 | 0.240 |
Why?
|
| Databases, Factual | 2 | 2016 | 7729 | 0.240 |
Why?
|
| Inflammation | 11 | 2020 | 10629 | 0.240 |
Why?
|
| Vitamins | 2 | 2021 | 1622 | 0.240 |
Why?
|
| Health Behavior | 1 | 2016 | 2634 | 0.240 |
Why?
|
| C-Reactive Protein | 10 | 2019 | 3778 | 0.240 |
Why?
|
| Residence Characteristics | 1 | 2014 | 2050 | 0.240 |
Why?
|
| Antioxidants | 5 | 2020 | 1658 | 0.240 |
Why?
|
| Interleukin-6 | 9 | 2020 | 3208 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2020 | 10940 | 0.230 |
Why?
|
| Nitroglycerin | 5 | 2015 | 325 | 0.230 |
Why?
|
| MicroRNAs | 2 | 2018 | 3750 | 0.230 |
Why?
|
| Body Mass Index | 17 | 2020 | 12718 | 0.230 |
Why?
|
| Congresses as Topic | 1 | 2008 | 763 | 0.230 |
Why?
|
| Population Surveillance | 1 | 2014 | 2614 | 0.220 |
Why?
|
| Quality Improvement | 1 | 2018 | 3750 | 0.220 |
Why?
|
| Placebos | 10 | 2018 | 1674 | 0.220 |
Why?
|
| Sex Factors | 8 | 2020 | 10394 | 0.220 |
Why?
|
| Guidelines as Topic | 3 | 2016 | 1404 | 0.220 |
Why?
|
| Synovial Fluid | 4 | 2020 | 394 | 0.220 |
Why?
|
| Enzyme Inhibitors | 4 | 2009 | 3794 | 0.220 |
Why?
|
| Electronic Health Records | 2 | 2016 | 4467 | 0.220 |
Why?
|
| Fatty Acids, Omega-6 | 2 | 2015 | 227 | 0.220 |
Why?
|
| Biomedical Research | 2 | 2017 | 3308 | 0.220 |
Why?
|
| Ventricular Dysfunction | 1 | 2003 | 143 | 0.220 |
Why?
|
| Erectile Dysfunction | 1 | 2006 | 436 | 0.220 |
Why?
|
| Exercise | 4 | 2018 | 5611 | 0.220 |
Why?
|
| Cooperative Behavior | 4 | 2018 | 1503 | 0.210 |
Why?
|
| Health Care Costs | 4 | 2020 | 3207 | 0.210 |
Why?
|
| Genetic Variation | 3 | 2021 | 6535 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 15518 | 0.210 |
Why?
|
| Up-Regulation | 7 | 2020 | 4221 | 0.210 |
Why?
|
| Hong Kong | 2 | 2019 | 148 | 0.210 |
Why?
|
| Pediatrics | 1 | 2017 | 3474 | 0.210 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 658 | 0.200 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 39001 | 0.200 |
Why?
|
| Kidney Diseases | 2 | 2011 | 2146 | 0.200 |
Why?
|
| Body Composition | 4 | 2010 | 2401 | 0.200 |
Why?
|
| Galactosylceramides | 3 | 2017 | 92 | 0.200 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2017 | 805 | 0.200 |
Why?
|
| Lymphocyte Activation | 5 | 2019 | 5524 | 0.200 |
Why?
|
| Interleukin-12 | 3 | 2019 | 577 | 0.200 |
Why?
|
| Drug Tolerance | 2 | 2021 | 376 | 0.190 |
Why?
|
| Antigens, CD1 | 5 | 2012 | 437 | 0.190 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2017 | 1213 | 0.190 |
Why?
|
| Subtilisins | 1 | 2021 | 83 | 0.190 |
Why?
|
| Vitamin K 1 | 1 | 2021 | 48 | 0.190 |
Why?
|
| RNA, Messenger | 4 | 2017 | 13028 | 0.190 |
Why?
|
| Xanthomatosis | 2 | 2018 | 32 | 0.190 |
Why?
|
| Nitric Oxide | 2 | 2011 | 2132 | 0.190 |
Why?
|
| Heredity | 3 | 2018 | 154 | 0.190 |
Why?
|
| Time Factors | 18 | 2020 | 40038 | 0.190 |
Why?
|
| Down-Regulation | 6 | 2019 | 3000 | 0.190 |
Why?
|
| Quality of Health Care | 1 | 2016 | 4370 | 0.190 |
Why?
|
| Cholesterol Ester Transfer Proteins | 3 | 2007 | 113 | 0.190 |
Why?
|
| Interleukin-18 | 2 | 2019 | 249 | 0.190 |
Why?
|
| Cardiovascular Agents | 1 | 2007 | 850 | 0.190 |
Why?
|
| Smoking | 6 | 2018 | 8984 | 0.190 |
Why?
|
| Queensland | 1 | 2020 | 37 | 0.190 |
Why?
|
| Case-Control Studies | 14 | 2020 | 21733 | 0.180 |
Why?
|
| Matrix Metalloproteinase 3 | 3 | 2020 | 133 | 0.180 |
Why?
|
| Fluorine Radioisotopes | 2 | 2020 | 443 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 1070 | 0.180 |
Why?
|
| New Zealand | 4 | 2015 | 355 | 0.180 |
Why?
|
| Waist Circumference | 5 | 2020 | 917 | 0.180 |
Why?
|
| Prospective Studies | 18 | 2021 | 53250 | 0.180 |
Why?
|
| Patient Selection | 3 | 2019 | 4210 | 0.180 |
Why?
|
| Colchicine | 1 | 2021 | 244 | 0.180 |
Why?
|
| Hyperlipoproteinemia Type I | 1 | 2019 | 7 | 0.180 |
Why?
|
| Nutrition Surveys | 2 | 2018 | 1660 | 0.180 |
Why?
|
| Obesity, Morbid | 1 | 2010 | 1213 | 0.180 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 8035 | 0.180 |
Why?
|
| Radiopharmaceuticals | 2 | 2020 | 2647 | 0.170 |
Why?
|
| Inflammation Mediators | 3 | 2018 | 1888 | 0.170 |
Why?
|
| Arterioles | 2 | 2010 | 254 | 0.170 |
Why?
|
| Elasticity | 3 | 2007 | 657 | 0.170 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2021 | 155 | 0.170 |
Why?
|
| Chemistry, Clinical | 2 | 2016 | 63 | 0.170 |
Why?
|
| Blood Flow Velocity | 5 | 2009 | 1423 | 0.170 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 871 | 0.170 |
Why?
|
| Signal Transduction | 13 | 2020 | 23398 | 0.170 |
Why?
|
| Primary Prevention | 3 | 2019 | 1167 | 0.170 |
Why?
|
| Endothelial Cells | 5 | 2020 | 3482 | 0.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2020 | 4422 | 0.170 |
Why?
|
| Markov Chains | 2 | 2020 | 968 | 0.170 |
Why?
|
| Social Support | 2 | 2020 | 2118 | 0.160 |
Why?
|
| Plethysmography | 4 | 2006 | 180 | 0.160 |
Why?
|
| Benzoxazoles | 1 | 2019 | 79 | 0.160 |
Why?
|
| Butyrates | 1 | 2019 | 165 | 0.160 |
Why?
|
| Interdisciplinary Communication | 2 | 2014 | 950 | 0.160 |
Why?
|
| Disease Progression | 5 | 2020 | 13273 | 0.160 |
Why?
|
| Compliance | 2 | 2010 | 104 | 0.160 |
Why?
|
| Antihypertensive Agents | 3 | 2017 | 2047 | 0.160 |
Why?
|
| Research Design | 5 | 2017 | 5983 | 0.160 |
Why?
|
| Logistic Models | 5 | 2019 | 13404 | 0.160 |
Why?
|
| Albuminuria | 2 | 2014 | 681 | 0.160 |
Why?
|
| Retrospective Studies | 16 | 2021 | 77410 | 0.160 |
Why?
|
| Antigen Presentation | 3 | 2010 | 1283 | 0.150 |
Why?
|
| Antibodies, Viral | 2 | 2021 | 3175 | 0.150 |
Why?
|
| Diabetes Mellitus | 5 | 2020 | 5752 | 0.150 |
Why?
|
| Receptors, OSM-LIF | 1 | 2017 | 15 | 0.150 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2015 | 194 | 0.150 |
Why?
|
| Interleukin-1alpha | 1 | 2017 | 85 | 0.150 |
Why?
|
| Reference Values | 6 | 2021 | 4974 | 0.150 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2017 | 61 | 0.150 |
Why?
|
| Severity of Illness Index | 9 | 2018 | 15526 | 0.150 |
Why?
|
| Community Mental Health Services | 1 | 2020 | 386 | 0.150 |
Why?
|
| Efficiency | 1 | 2020 | 462 | 0.150 |
Why?
|
| Anthropometry | 3 | 2012 | 1348 | 0.150 |
Why?
|
| Liposomes | 2 | 2019 | 759 | 0.150 |
Why?
|
| Apolipoprotein C-II | 1 | 2016 | 11 | 0.150 |
Why?
|
| Antigens, Bacterial | 3 | 2013 | 1172 | 0.150 |
Why?
|
| Leukotriene B4 | 1 | 2018 | 294 | 0.150 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2020 | 1683 | 0.140 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2019 | 379 | 0.140 |
Why?
|
| Blood Vessels | 1 | 2003 | 1124 | 0.140 |
Why?
|
| Risk | 5 | 2017 | 9677 | 0.140 |
Why?
|
| Delayed-Action Preparations | 3 | 2015 | 967 | 0.140 |
Why?
|
| Glycoproteins | 3 | 2010 | 2266 | 0.140 |
Why?
|
| Multifactorial Inheritance | 2 | 2014 | 1195 | 0.140 |
Why?
|
| Deuterium | 2 | 2015 | 101 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 2727 | 0.140 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2014 | 1503 | 0.140 |
Why?
|
| Allopurinol | 1 | 2018 | 190 | 0.140 |
Why?
|
| Cytokines | 6 | 2019 | 7324 | 0.140 |
Why?
|
| Awareness | 1 | 2021 | 639 | 0.140 |
Why?
|
| RNA, Small Interfering | 4 | 2020 | 3504 | 0.140 |
Why?
|
| Asia | 1 | 2018 | 609 | 0.140 |
Why?
|
| Nutrition Policy | 1 | 2020 | 488 | 0.140 |
Why?
|
| Evidence-Based Medicine | 4 | 2018 | 3608 | 0.140 |
Why?
|
| Postmenopause | 2 | 2015 | 2458 | 0.140 |
Why?
|
| Loneliness | 1 | 2018 | 186 | 0.140 |
Why?
|
| Coronary Angiography | 5 | 2020 | 4576 | 0.140 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 1537 | 0.140 |
Why?
|
| Tunica Intima | 2 | 2009 | 463 | 0.140 |
Why?
|
| Administration, Oral | 7 | 2020 | 3912 | 0.140 |
Why?
|
| Autocrine Communication | 1 | 2017 | 171 | 0.140 |
Why?
|
| Heart Rate | 5 | 2013 | 4091 | 0.140 |
Why?
|
| Alcohols | 2 | 2008 | 92 | 0.140 |
Why?
|
| Norpregnenes | 1 | 2015 | 7 | 0.130 |
Why?
|
| Serum Amyloid P-Component | 1 | 2016 | 47 | 0.130 |
Why?
|
| Particle Size | 5 | 2015 | 1639 | 0.130 |
Why?
|
| Overweight | 3 | 2016 | 2371 | 0.130 |
Why?
|
| Pulse | 2 | 2006 | 228 | 0.130 |
Why?
|
| Linear Models | 5 | 2020 | 5952 | 0.130 |
Why?
|
| Gene Expression Regulation | 6 | 2019 | 12066 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 3 | 2015 | 2167 | 0.130 |
Why?
|
| Social Perception | 1 | 2019 | 425 | 0.130 |
Why?
|
| Medical History Taking | 3 | 2020 | 782 | 0.130 |
Why?
|
| Social Isolation | 1 | 2018 | 367 | 0.130 |
Why?
|
| Osteoarthritis | 3 | 2019 | 1035 | 0.130 |
Why?
|
| Plasma | 1 | 2018 | 575 | 0.130 |
Why?
|
| Expert Systems | 1 | 2015 | 81 | 0.130 |
Why?
|
| Thiazoles | 2 | 2014 | 1482 | 0.130 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2019 | 397 | 0.130 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2011 | 689 | 0.130 |
Why?
|
| Rare Diseases | 1 | 2020 | 552 | 0.130 |
Why?
|
| Aged, 80 and over | 12 | 2021 | 57744 | 0.130 |
Why?
|
| Fish Oils | 4 | 2018 | 470 | 0.130 |
Why?
|
| Drug Compounding | 4 | 2020 | 241 | 0.130 |
Why?
|
| Sphingomyelins | 1 | 2015 | 106 | 0.130 |
Why?
|
| Glucosylceramides | 1 | 2014 | 28 | 0.120 |
Why?
|
| Peroxidase | 1 | 2018 | 611 | 0.120 |
Why?
|
| Protease Inhibitors | 1 | 2018 | 792 | 0.120 |
Why?
|
| Genetics, Population | 1 | 2019 | 933 | 0.120 |
Why?
|
| Comorbidity | 6 | 2020 | 10380 | 0.120 |
Why?
|
| Self-Help Groups | 1 | 2016 | 190 | 0.120 |
Why?
|
| Neutrophils | 2 | 2018 | 3718 | 0.120 |
Why?
|
| Exercise Therapy | 2 | 2016 | 904 | 0.120 |
Why?
|
| Glutathione | 1 | 2017 | 590 | 0.120 |
Why?
|
| Patient Care Team | 2 | 2020 | 2528 | 0.120 |
Why?
|
| Chylomicron Remnants | 2 | 2012 | 3 | 0.120 |
Why?
|
| Models, Psychological | 1 | 2018 | 807 | 0.120 |
Why?
|
| Affective Disorders, Psychotic | 1 | 2015 | 191 | 0.120 |
Why?
|
| Data Mining | 2 | 2016 | 537 | 0.120 |
Why?
|
| Chalcones | 1 | 2014 | 28 | 0.120 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2015 | 281 | 0.120 |
Why?
|
| Ceramides | 1 | 2015 | 199 | 0.120 |
Why?
|
| Interleukin-17 | 1 | 2020 | 902 | 0.120 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2006 | 1813 | 0.110 |
Why?
|
| Cost Sharing | 1 | 2017 | 407 | 0.110 |
Why?
|
| Interinstitutional Relations | 1 | 2014 | 240 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2019 | 2074 | 0.110 |
Why?
|
| Propionates | 1 | 2014 | 169 | 0.110 |
Why?
|
| Myocardial Revascularization | 1 | 2017 | 841 | 0.110 |
Why?
|
| Sphingolipids | 1 | 2014 | 159 | 0.110 |
Why?
|
| Internet | 2 | 2016 | 3058 | 0.110 |
Why?
|
| South Africa | 1 | 2018 | 1731 | 0.110 |
Why?
|
| Reproducibility of Results | 8 | 2019 | 19894 | 0.110 |
Why?
|
| Cells, Cultured | 10 | 2020 | 19232 | 0.110 |
Why?
|
| Serine | 1 | 2017 | 825 | 0.110 |
Why?
|
| Quality of Life | 4 | 2020 | 12788 | 0.110 |
Why?
|
| NAD | 1 | 2017 | 590 | 0.110 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2015 | 426 | 0.110 |
Why?
|
| Clinical Chemistry Tests | 1 | 2013 | 61 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2017 | 1460 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2012 | 57 | 0.110 |
Why?
|
| Transcription Factors | 3 | 2020 | 12209 | 0.110 |
Why?
|
| Antigen-Presenting Cells | 3 | 2013 | 972 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2019 | 1836 | 0.110 |
Why?
|
| Cholic Acids | 1 | 2012 | 41 | 0.110 |
Why?
|
| Single-Blind Method | 3 | 2013 | 1586 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2019 | 1837 | 0.110 |
Why?
|
| Sensitivity and Specificity | 5 | 2021 | 14714 | 0.110 |
Why?
|
| Republic of Korea | 1 | 2014 | 538 | 0.110 |
Why?
|
| Cholesterol Esters | 2 | 2002 | 74 | 0.110 |
Why?
|
| Consanguinity | 1 | 2014 | 455 | 0.110 |
Why?
|
| Acetates | 1 | 2014 | 310 | 0.110 |
Why?
|
| Aortic Valve | 2 | 2021 | 1920 | 0.110 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2012 | 133 | 0.100 |
Why?
|
| Insulin-Secreting Cells | 1 | 2020 | 889 | 0.100 |
Why?
|
| Self Efficacy | 1 | 2016 | 615 | 0.100 |
Why?
|
| Multivariate Analysis | 6 | 2020 | 12243 | 0.100 |
Why?
|
| Health Education | 1 | 2019 | 1056 | 0.100 |
Why?
|
| Spain | 3 | 2019 | 464 | 0.100 |
Why?
|
| Health Services | 1 | 2017 | 758 | 0.100 |
Why?
|
| von Willebrand Factor | 1 | 2015 | 669 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2019 | 3591 | 0.100 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2011 | 140 | 0.100 |
Why?
|
| Death | 1 | 2016 | 678 | 0.100 |
Why?
|
| Protein Structure, Secondary | 1 | 2015 | 1245 | 0.100 |
Why?
|
| PPAR delta | 1 | 2011 | 43 | 0.100 |
Why?
|
| Ideal Body Weight | 1 | 2011 | 27 | 0.100 |
Why?
|
| ROC Curve | 1 | 2019 | 3527 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 2 | 2016 | 2715 | 0.100 |
Why?
|
| Drug Combinations | 2 | 2016 | 1958 | 0.100 |
Why?
|
| Premenopause | 1 | 2015 | 1033 | 0.100 |
Why?
|
| Anticoagulants | 2 | 2018 | 4599 | 0.100 |
Why?
|
| Endothelin-1 | 1 | 2013 | 314 | 0.100 |
Why?
|
| Radial Artery | 1 | 2013 | 193 | 0.100 |
Why?
|
| Attitude | 1 | 2016 | 775 | 0.100 |
Why?
|
| F2-Isoprostanes | 4 | 2016 | 35 | 0.100 |
Why?
|
| Models, Organizational | 1 | 2014 | 574 | 0.100 |
Why?
|
| American Heart Association | 1 | 2015 | 1057 | 0.100 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 12954 | 0.090 |
Why?
|
| Lymphocytes | 1 | 2019 | 2615 | 0.090 |
Why?
|
| beta-Glucans | 1 | 2011 | 123 | 0.090 |
Why?
|
| Endocytosis | 2 | 2012 | 985 | 0.090 |
Why?
|
| Repressor Proteins | 2 | 2020 | 3024 | 0.090 |
Why?
|
| Angiography | 1 | 2016 | 1638 | 0.090 |
Why?
|
| Prediabetic State | 1 | 2016 | 499 | 0.090 |
Why?
|
| Community Networks | 1 | 2012 | 203 | 0.090 |
Why?
|
| Telephone | 1 | 2014 | 617 | 0.090 |
Why?
|
| Atrial Fibrillation | 2 | 2021 | 5033 | 0.090 |
Why?
|
| Calcium | 2 | 2021 | 5755 | 0.090 |
Why?
|
| Hyperemia | 1 | 2012 | 225 | 0.090 |
Why?
|
| HIV Infections | 2 | 2019 | 16715 | 0.090 |
Why?
|
| Apolipoproteins E | 2 | 2015 | 1436 | 0.090 |
Why?
|
| Aspergillus fumigatus | 1 | 2011 | 150 | 0.090 |
Why?
|
| Program Development | 1 | 2017 | 1314 | 0.090 |
Why?
|
| Cardiovascular System | 2 | 2016 | 828 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 2419 | 0.090 |
Why?
|
| Caloric Restriction | 1 | 2013 | 302 | 0.090 |
Why?
|
| Genetic Counseling | 1 | 2014 | 600 | 0.090 |
Why?
|
| Coronary Vessels | 2 | 2020 | 3106 | 0.090 |
Why?
|
| Sulfoglycosphingolipids | 1 | 2009 | 19 | 0.090 |
Why?
|
| Japan | 1 | 2014 | 1360 | 0.090 |
Why?
|
| Pathology, Clinical | 1 | 2014 | 368 | 0.090 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2011 | 95 | 0.090 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2019 | 1187 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2020 | 2583 | 0.090 |
Why?
|
| Antigens | 2 | 2015 | 1466 | 0.090 |
Why?
|
| Immunoassay | 3 | 2010 | 751 | 0.090 |
Why?
|
| Biological Products | 1 | 2019 | 859 | 0.090 |
Why?
|
| Calcinosis | 1 | 2018 | 1495 | 0.090 |
Why?
|
| Aspergillosis | 1 | 2011 | 235 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2019 | 1580 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 2016 | 820 | 0.090 |
Why?
|
| Glycosphingolipids | 1 | 2010 | 79 | 0.090 |
Why?
|
| Age Distribution | 4 | 2016 | 2899 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1937 | 0.090 |
Why?
|
| Drug Design | 1 | 2015 | 1075 | 0.090 |
Why?
|
| Decision Trees | 1 | 2011 | 506 | 0.090 |
Why?
|
| Homocysteine | 3 | 2008 | 647 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 4561 | 0.080 |
Why?
|
| Lipoproteins, IDL | 3 | 2003 | 18 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 2916 | 0.080 |
Why?
|
| Blood Coagulation | 1 | 2015 | 1127 | 0.080 |
Why?
|
| Mice | 20 | 2020 | 81154 | 0.080 |
Why?
|
| Income | 1 | 2018 | 1913 | 0.080 |
Why?
|
| Fruit | 1 | 2014 | 1141 | 0.080 |
Why?
|
| Anaphylaxis | 1 | 2016 | 746 | 0.080 |
Why?
|
| Blood Platelets | 2 | 2010 | 2509 | 0.080 |
Why?
|
| Vegetables | 1 | 2014 | 1181 | 0.080 |
Why?
|
| Community Health Services | 1 | 2014 | 650 | 0.080 |
Why?
|
| Quinolines | 1 | 2014 | 732 | 0.080 |
Why?
|
| Models, Economic | 1 | 2013 | 712 | 0.080 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 500 | 0.080 |
Why?
|
| Alberta | 1 | 2008 | 64 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2015 | 1115 | 0.080 |
Why?
|
| omega-N-Methylarginine | 2 | 2005 | 111 | 0.080 |
Why?
|
| Cell Wall | 1 | 2011 | 422 | 0.080 |
Why?
|
| Trichinella spiralis | 1 | 2008 | 28 | 0.080 |
Why?
|
| Trichinellosis | 1 | 2008 | 36 | 0.080 |
Why?
|
| Cohort Studies | 11 | 2021 | 40545 | 0.080 |
Why?
|
| Metabolomics | 1 | 2017 | 1487 | 0.080 |
Why?
|
| Mast Cells | 2 | 2008 | 1544 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 1636 | 0.080 |
Why?
|
| Nanoparticles | 1 | 2020 | 1898 | 0.080 |
Why?
|
| Referral and Consultation | 3 | 2016 | 3530 | 0.080 |
Why?
|
| Triazoles | 1 | 2014 | 904 | 0.080 |
Why?
|
| Cell-Derived Microparticles | 1 | 2010 | 168 | 0.080 |
Why?
|
| Ultracentrifugation | 1 | 2008 | 182 | 0.080 |
Why?
|
| Patient Care Management | 1 | 2011 | 306 | 0.080 |
Why?
|
| Nitroprusside | 2 | 2005 | 275 | 0.080 |
Why?
|
| Diastole | 2 | 2008 | 791 | 0.080 |
Why?
|
| Carbon Isotopes | 3 | 2003 | 468 | 0.080 |
Why?
|
| Thymus Gland | 1 | 2012 | 1266 | 0.080 |
Why?
|
| Esters | 2 | 2013 | 210 | 0.080 |
Why?
|
| Aging | 2 | 2020 | 8655 | 0.080 |
Why?
|
| Thiazolidinediones | 1 | 2011 | 475 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2014 | 2538 | 0.080 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2007 | 34 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2005 | 1678 | 0.070 |
Why?
|
| Tunica Media | 1 | 2007 | 112 | 0.070 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2007 | 56 | 0.070 |
Why?
|
| Adaptation, Biological | 1 | 2008 | 152 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2016 | 3874 | 0.070 |
Why?
|
| Thrombosis | 2 | 2018 | 2968 | 0.070 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2007 | 93 | 0.070 |
Why?
|
| Proteins | 2 | 2017 | 6098 | 0.070 |
Why?
|
| Interleukins | 1 | 2011 | 791 | 0.070 |
Why?
|
| Tryptases | 1 | 2008 | 190 | 0.070 |
Why?
|
| World Health Organization | 2 | 2016 | 1317 | 0.070 |
Why?
|
| Diet, Mediterranean | 1 | 2013 | 700 | 0.070 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 3839 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 4803 | 0.070 |
Why?
|
| GATA6 Transcription Factor | 1 | 2006 | 50 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 6170 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2012 | 6356 | 0.070 |
Why?
|
| Smoking Cessation | 1 | 2018 | 2071 | 0.070 |
Why?
|
| Stroke Volume | 2 | 2013 | 5002 | 0.070 |
Why?
|
| Publication Bias | 2 | 2018 | 162 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2019 | 10477 | 0.070 |
Why?
|
| Aortic Valve Stenosis | 1 | 2018 | 1955 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 2291 | 0.070 |
Why?
|
| Critical Pathways | 1 | 2010 | 476 | 0.070 |
Why?
|
| Acetylcholine | 2 | 2005 | 619 | 0.070 |
Why?
|
| Racemases and Epimerases | 1 | 2006 | 113 | 0.070 |
Why?
|
| Pandemics | 3 | 2020 | 8385 | 0.070 |
Why?
|
| Coenzymes | 2 | 2003 | 91 | 0.070 |
Why?
|
| Hyperandrogenism | 1 | 2005 | 38 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 1340 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 9440 | 0.070 |
Why?
|
| Catecholamines | 1 | 2006 | 387 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2011 | 2971 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 1534 | 0.070 |
Why?
|
| Heart | 1 | 2018 | 4460 | 0.060 |
Why?
|
| DNA | 2 | 2019 | 7295 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 1670 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2009 | 1794 | 0.060 |
Why?
|
| Immunity, Innate | 3 | 2019 | 2961 | 0.060 |
Why?
|
| Hypotension | 1 | 2011 | 884 | 0.060 |
Why?
|
| Societies, Medical | 4 | 2020 | 3740 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 2281 | 0.060 |
Why?
|
| Isotopes | 1 | 2004 | 124 | 0.060 |
Why?
|
| STAT4 Transcription Factor | 2 | 2017 | 96 | 0.060 |
Why?
|
| Europe | 3 | 2016 | 3336 | 0.060 |
Why?
|
| Radioactive Tracers | 2 | 2015 | 72 | 0.060 |
Why?
|
| Sialic Acids | 1 | 2004 | 128 | 0.060 |
Why?
|
| Breath Tests | 2 | 2003 | 280 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2018 | 5316 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 560 | 0.060 |
Why?
|
| Eating | 1 | 2011 | 1536 | 0.060 |
Why?
|
| Receptor, Insulin | 1 | 2008 | 846 | 0.060 |
Why?
|
| Protons | 1 | 2009 | 1129 | 0.060 |
Why?
|
| Developing Countries | 1 | 2016 | 2815 | 0.060 |
Why?
|
| Survival Rate | 1 | 2018 | 12786 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2005 | 460 | 0.060 |
Why?
|
| Decision Making | 1 | 2017 | 3887 | 0.060 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2017 | 277 | 0.060 |
Why?
|
| Placebo Effect | 2 | 2018 | 503 | 0.060 |
Why?
|
| Sterols | 1 | 2003 | 63 | 0.060 |
Why?
|
| Milk | 2 | 2017 | 449 | 0.060 |
Why?
|
| Photoplethysmography | 1 | 2003 | 56 | 0.060 |
Why?
|
| Protein Transport | 4 | 2013 | 1988 | 0.050 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2020 | 571 | 0.050 |
Why?
|
| Child, Preschool | 5 | 2019 | 40964 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2018 | 4687 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 1831 | 0.050 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2006 | 321 | 0.050 |
Why?
|
| Intracellular Fluid | 1 | 2002 | 203 | 0.050 |
Why?
|
| Monomeric Clathrin Assembly Proteins | 1 | 2002 | 24 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 2211 | 0.050 |
Why?
|
| Ischemia | 2 | 2020 | 1907 | 0.050 |
Why?
|
| Hypertension, Renal | 1 | 2003 | 177 | 0.050 |
Why?
|
| Asparagine | 1 | 2002 | 122 | 0.050 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2002 | 58 | 0.050 |
Why?
|
| Finland | 2 | 2015 | 602 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 717 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 7 | 2020 | 21824 | 0.050 |
Why?
|
| Oxazolone | 1 | 2002 | 60 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 6237 | 0.050 |
Why?
|
| Blood Circulation | 1 | 2003 | 251 | 0.050 |
Why?
|
| Electric Impedance | 2 | 2004 | 729 | 0.050 |
Why?
|
| Genomics | 1 | 2018 | 5714 | 0.050 |
Why?
|
| Electron Transport | 1 | 2003 | 211 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2009 | 2217 | 0.050 |
Why?
|
| Antipsychotic Agents | 1 | 2015 | 3057 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2014 | 3187 | 0.050 |
Why?
|
| Retroperitoneal Space | 1 | 2002 | 176 | 0.050 |
Why?
|
| Central Nervous System Depressants | 1 | 2003 | 167 | 0.050 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 4931 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 2278 | 0.050 |
Why?
|
| Protein Binding | 5 | 2019 | 9377 | 0.050 |
Why?
|
| Fibrinolysis | 1 | 2003 | 322 | 0.050 |
Why?
|
| Health Promotion | 2 | 2013 | 2205 | 0.050 |
Why?
|
| Autonomic Nervous System | 1 | 2006 | 671 | 0.050 |
Why?
|
| Peritoneum | 1 | 2002 | 227 | 0.050 |
Why?
|
| Immunoglobulin E | 2 | 2008 | 1463 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2014 | 8316 | 0.050 |
Why?
|
| Age of Onset | 2 | 2018 | 3268 | 0.050 |
Why?
|
| Plasmapheresis | 1 | 2002 | 211 | 0.050 |
Why?
|
| Sulfhydryl Compounds | 1 | 2002 | 298 | 0.050 |
Why?
|
| Collagen | 1 | 2010 | 2681 | 0.050 |
Why?
|
| Protein Isoforms | 3 | 2019 | 1729 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2016 | 4251 | 0.050 |
Why?
|
| Health Care Surveys | 2 | 2018 | 2453 | 0.050 |
Why?
|
| Interleukin-13 | 1 | 2003 | 389 | 0.050 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 72 | 0.050 |
Why?
|
| Cell Adhesion | 3 | 2019 | 3144 | 0.050 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12354 | 0.050 |
Why?
|
| Menopause | 2 | 2020 | 1626 | 0.050 |
Why?
|
| Limit of Detection | 1 | 2021 | 265 | 0.050 |
Why?
|
| Aspirin | 2 | 2018 | 3283 | 0.050 |
Why?
|
| Tea | 1 | 2002 | 274 | 0.050 |
Why?
|
| Chemokine CXCL2 | 1 | 2020 | 116 | 0.050 |
Why?
|
| Chronic Disease | 3 | 2011 | 9139 | 0.050 |
Why?
|
| Serbia | 1 | 2019 | 15 | 0.040 |
Why?
|
| Chemokine CXCL1 | 1 | 2020 | 101 | 0.040 |
Why?
|
| Monocytes | 2 | 2020 | 2593 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2016 | 2298 | 0.040 |
Why?
|
| Membrane Proteins | 3 | 2008 | 7880 | 0.040 |
Why?
|
| Isotretinoin | 1 | 2020 | 114 | 0.040 |
Why?
|
| Amides | 1 | 2002 | 459 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2003 | 670 | 0.040 |
Why?
|
| Abdomen | 2 | 2004 | 1117 | 0.040 |
Why?
|
| Echocardiography | 2 | 2009 | 5096 | 0.040 |
Why?
|
| Cell Line | 6 | 2013 | 15993 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2002 | 675 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2003 | 546 | 0.040 |
Why?
|
| Androgens | 1 | 2007 | 1247 | 0.040 |
Why?
|
| Echocardiography, Doppler | 1 | 2003 | 935 | 0.040 |
Why?
|
| Platelet Aggregation | 1 | 2003 | 798 | 0.040 |
Why?
|
| Chemotactic Factors | 1 | 2020 | 199 | 0.040 |
Why?
|
| Transfection | 3 | 2015 | 5892 | 0.040 |
Why?
|
| Mathematical Concepts | 1 | 2019 | 63 | 0.040 |
Why?
|
| Phosphorylation | 3 | 2019 | 8436 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2002 | 1202 | 0.040 |
Why?
|
| Macrophages | 3 | 2013 | 5651 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2009 | 3758 | 0.040 |
Why?
|
| United States | 4 | 2021 | 69859 | 0.040 |
Why?
|
| Joint Capsule | 1 | 2019 | 68 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2011 | 9848 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2020 | 275 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 2017 | 0.040 |
Why?
|
| Alcohol Drinking | 3 | 2014 | 3965 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2010 | 2148 | 0.040 |
Why?
|
| Glucose Intolerance | 1 | 2003 | 577 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 4665 | 0.040 |
Why?
|
| HeLa Cells | 3 | 2012 | 3130 | 0.040 |
Why?
|
| Mice, Transgenic | 4 | 2011 | 9731 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 2020 | 422 | 0.040 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2013 | 1832 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2002 | 2327 | 0.040 |
Why?
|
| Adipokines | 2 | 2011 | 320 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 188 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2020 | 2500 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 5867 | 0.040 |
Why?
|
| Viscera | 3 | 2003 | 139 | 0.040 |
Why?
|
| Gene Frequency | 3 | 2014 | 3585 | 0.040 |
Why?
|
| Vietnam | 1 | 2018 | 408 | 0.040 |
Why?
|
| Carbon Dioxide | 1 | 2002 | 1150 | 0.040 |
Why?
|
| Scotland | 1 | 2017 | 155 | 0.040 |
Why?
|
| Lysine | 1 | 2002 | 1007 | 0.040 |
Why?
|
| Cell Movement | 1 | 2009 | 5216 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2012 | 5100 | 0.040 |
Why?
|
| Microcirculation | 1 | 2002 | 1287 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2005 | 2018 | 0.040 |
Why?
|
| Italy | 1 | 2019 | 829 | 0.040 |
Why?
|
| Health Priorities | 1 | 2020 | 380 | 0.040 |
Why?
|
| Extracellular Matrix | 3 | 2010 | 1743 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2008 | 3038 | 0.040 |
Why?
|
| Blood Proteins | 2 | 2013 | 1125 | 0.040 |
Why?
|
| Public Health | 2 | 2020 | 2603 | 0.040 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2003 | 811 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 667 | 0.040 |
Why?
|
| Platelet Function Tests | 1 | 2018 | 270 | 0.040 |
Why?
|
| Schizophrenia | 1 | 2015 | 6865 | 0.040 |
Why?
|
| Hospitalization | 4 | 2020 | 10259 | 0.040 |
Why?
|
| Virus Internalization | 1 | 2020 | 501 | 0.040 |
Why?
|
| Cattle | 2 | 2014 | 3917 | 0.030 |
Why?
|
| Ethanol | 1 | 2003 | 1343 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2014 | 2712 | 0.030 |
Why?
|
| Spleen | 3 | 2011 | 2359 | 0.030 |
Why?
|
| Organ Culture Techniques | 2 | 2010 | 813 | 0.030 |
Why?
|
| Acne Vulgaris | 1 | 2020 | 302 | 0.030 |
Why?
|
| Resistance Training | 1 | 2018 | 164 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2004 | 1986 | 0.030 |
Why?
|
| Endosomes | 2 | 2012 | 518 | 0.030 |
Why?
|
| Platelet Membrane Glycoproteins | 2 | 2010 | 293 | 0.030 |
Why?
|
| Diabetic Nephropathies | 1 | 2003 | 984 | 0.030 |
Why?
|
| Rabbits | 1 | 2002 | 4894 | 0.030 |
Why?
|
| Immunologic Memory | 2 | 2012 | 1347 | 0.030 |
Why?
|
| England | 1 | 2016 | 522 | 0.030 |
Why?
|
| Public Opinion | 1 | 2019 | 477 | 0.030 |
Why?
|
| Models, Animal | 1 | 2002 | 2172 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2016 | 434 | 0.030 |
Why?
|
| Arcus Senilis | 1 | 2014 | 3 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 494 | 0.030 |
Why?
|
| Economics, Medical | 1 | 2015 | 113 | 0.030 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2014 | 94 | 0.030 |
Why?
|
| Sympathetic Nervous System | 1 | 2017 | 513 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2014 | 223 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 2014 | 144 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 2014 | 148 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2016 | 438 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 2938 | 0.030 |
Why?
|
| Vaccines | 1 | 2003 | 823 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 1475 | 0.030 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2015 | 186 | 0.030 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2014 | 163 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2020 | 1356 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2021 | 1431 | 0.030 |
Why?
|
| Workflow | 1 | 2019 | 847 | 0.030 |
Why?
|
| Drug Stability | 1 | 2014 | 291 | 0.030 |
Why?
|
| Biological Assay | 1 | 2017 | 650 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2019 | 1880 | 0.030 |
Why?
|
| Viscosity | 1 | 2014 | 328 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2011 | 3772 | 0.030 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2008 | 236 | 0.030 |
Why?
|
| Diuretics | 1 | 2017 | 591 | 0.030 |
Why?
|
| Lipogenesis | 1 | 2015 | 212 | 0.030 |
Why?
|
| Glucosylceramidase | 1 | 2014 | 125 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2016 | 552 | 0.030 |
Why?
|
| Glycine | 1 | 2017 | 670 | 0.030 |
Why?
|
| RNA Stability | 1 | 2015 | 320 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2018 | 1252 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 601 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 277 | 0.030 |
Why?
|
| Access to Information | 1 | 2016 | 320 | 0.030 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2013 | 34 | 0.030 |
Why?
|
| Corynebacterium glutamicum | 1 | 2013 | 9 | 0.030 |
Why?
|
| Phosphatidylglycerols | 1 | 2013 | 34 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 2016 | 5096 | 0.030 |
Why?
|
| Software | 1 | 2007 | 4440 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2019 | 915 | 0.030 |
Why?
|
| Adiposity | 2 | 2015 | 1806 | 0.030 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 3155 | 0.030 |
Why?
|
| Alginates | 1 | 2014 | 252 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2005 | 3660 | 0.030 |
Why?
|
| Cardiolipins | 1 | 2013 | 88 | 0.030 |
Why?
|
| Musculoskeletal Diseases | 1 | 2019 | 581 | 0.030 |
Why?
|
| Office Visits | 1 | 2017 | 598 | 0.030 |
Why?
|
| Body Fluids | 1 | 2014 | 319 | 0.030 |
Why?
|
| Canada | 1 | 2018 | 2064 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 441 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 2017 | 926 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 906 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2006 | 6188 | 0.030 |
Why?
|
| Diffusion | 1 | 2014 | 831 | 0.030 |
Why?
|
| Rats | 2 | 2015 | 24250 | 0.030 |
Why?
|
| Renin-Angiotensin System | 1 | 2017 | 758 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 1364 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2014 | 2203 | 0.030 |
Why?
|
| Uric Acid | 1 | 2018 | 765 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2015 | 1004 | 0.030 |
Why?
|
| Sphingomonas | 1 | 2011 | 5 | 0.030 |
Why?
|
| Hybridomas | 1 | 2013 | 452 | 0.030 |
Why?
|
| Mice, Knockout | 3 | 2013 | 14563 | 0.030 |
Why?
|
| Transferrin | 1 | 2012 | 295 | 0.020 |
Why?
|
| Psychometrics | 1 | 2021 | 3000 | 0.020 |
Why?
|
| Surface Properties | 1 | 2014 | 1168 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 35122 | 0.020 |
Why?
|
| RNA Splice Sites | 1 | 2012 | 209 | 0.020 |
Why?
|
| Lysosomes | 2 | 2009 | 893 | 0.020 |
Why?
|
| Guinea Pigs | 2 | 2003 | 1386 | 0.020 |
Why?
|
| Marijuana Smoking | 1 | 2014 | 253 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2019 | 1349 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2012 | 328 | 0.020 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 824 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 935 | 0.020 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2012 | 246 | 0.020 |
Why?
|
| Leukocytes | 1 | 2019 | 2044 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2013 | 430 | 0.020 |
Why?
|
| Sleep | 1 | 2006 | 4619 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2014 | 733 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2012 | 500 | 0.020 |
Why?
|
| Netherlands | 1 | 2015 | 2170 | 0.020 |
Why?
|
| Systole | 2 | 2003 | 958 | 0.020 |
Why?
|
| Receptors, Collagen | 1 | 2010 | 26 | 0.020 |
Why?
|
| Ligands | 2 | 2011 | 3281 | 0.020 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2009 | 22 | 0.020 |
Why?
|
| Organ Size | 1 | 2015 | 2241 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 2504 | 0.020 |
Why?
|
| Thinness | 1 | 2013 | 480 | 0.020 |
Why?
|
| Denmark | 1 | 2012 | 738 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 4749 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 1789 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 2183 | 0.020 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2011 | 278 | 0.020 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2009 | 91 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 765 | 0.020 |
Why?
|
| Introns | 1 | 2012 | 991 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 2556 | 0.020 |
Why?
|
| Protein Sorting Signals | 1 | 2010 | 281 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2013 | 593 | 0.020 |
Why?
|
| Warfarin | 1 | 2018 | 1497 | 0.020 |
Why?
|
| Energy Intake | 2 | 2010 | 2149 | 0.020 |
Why?
|
| Area Under Curve | 2 | 2003 | 1654 | 0.020 |
Why?
|
| Germinal Center | 1 | 2011 | 377 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2011 | 646 | 0.020 |
Why?
|
| Lipocalins | 1 | 2009 | 170 | 0.020 |
Why?
|
| Laboratories | 1 | 2012 | 462 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 2177 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2011 | 548 | 0.020 |
Why?
|
| MADS Domain Proteins | 1 | 2008 | 19 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2015 | 1184 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2019 | 5973 | 0.020 |
Why?
|
| Genome | 1 | 2017 | 1806 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 2162 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6539 | 0.020 |
Why?
|
| Cell Cycle Proteins | 2 | 2013 | 3463 | 0.020 |
Why?
|
| Body Weight | 3 | 2004 | 4670 | 0.020 |
Why?
|
| Myogenic Regulatory Factors | 1 | 2008 | 106 | 0.020 |
Why?
|
| Lipase | 1 | 2010 | 314 | 0.020 |
Why?
|
| Temperature | 1 | 2014 | 2202 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2012 | 1524 | 0.020 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2007 | 31 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 715 | 0.020 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2008 | 250 | 0.020 |
Why?
|
| Rural Population | 1 | 2018 | 2207 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 1157 | 0.020 |
Why?
|
| Fluorescence | 1 | 2010 | 752 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 5179 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2011 | 598 | 0.020 |
Why?
|
| Indoles | 1 | 2015 | 1841 | 0.020 |
Why?
|
| Counseling | 1 | 2015 | 1523 | 0.020 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 18027 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 2086 | 0.020 |
Why?
|
| Metformin | 1 | 2014 | 837 | 0.020 |
Why?
|
| Antibodies | 1 | 2015 | 2459 | 0.020 |
Why?
|
| Computational Biology | 1 | 2019 | 3515 | 0.020 |
Why?
|
| Isoelectric Focusing | 1 | 2006 | 180 | 0.020 |
Why?
|
| Isoleucine | 1 | 2006 | 112 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 2274 | 0.020 |
Why?
|
| Biological Availability | 1 | 2007 | 397 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2012 | 1537 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2010 | 1263 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 1574 | 0.020 |
Why?
|
| Gene Expression | 1 | 2019 | 7793 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 3070 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 20121 | 0.020 |
Why?
|
| Mortality | 1 | 2017 | 2862 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 2011 | 714 | 0.020 |
Why?
|
| Energy Transfer | 1 | 2005 | 109 | 0.020 |
Why?
|
| Dendritic Cells | 2 | 2009 | 2720 | 0.020 |
Why?
|
| Intestinal Absorption | 1 | 2007 | 420 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 3847 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2010 | 35409 | 0.020 |
Why?
|
| Weight Gain | 1 | 2015 | 2294 | 0.020 |
Why?
|
| Hormones, Ectopic | 1 | 2005 | 40 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2012 | 1782 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2006 | 410 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2015 | 2922 | 0.020 |
Why?
|
| Anti-Obesity Agents | 1 | 2008 | 217 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 2006 | 0.020 |
Why?
|
| Founder Effect | 1 | 2005 | 189 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2013 | 1099 | 0.020 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2005 | 94 | 0.020 |
Why?
|
| Schwann Cells | 1 | 2005 | 196 | 0.020 |
Why?
|
| Arthritis, Experimental | 1 | 2007 | 291 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2006 | 223 | 0.020 |
Why?
|
| Arthritis | 1 | 2010 | 661 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2005 | 464 | 0.020 |
Why?
|
| Peptides | 1 | 2016 | 4406 | 0.020 |
Why?
|
| Resistin | 1 | 2005 | 170 | 0.010 |
Why?
|
| Binding Sites | 1 | 2013 | 6111 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 1962 | 0.010 |
Why?
|
| Family | 1 | 2015 | 3144 | 0.010 |
Why?
|
| Proteomics | 1 | 2017 | 3639 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2012 | 2506 | 0.010 |
Why?
|
| Saponins | 1 | 2003 | 50 | 0.010 |
Why?
|
| Receptors, CCR3 | 1 | 2003 | 62 | 0.010 |
Why?
|
| Eosinophilia | 1 | 2008 | 541 | 0.010 |
Why?
|
| COS Cells | 1 | 2005 | 1161 | 0.010 |
Why?
|
| Eosinophils | 1 | 2008 | 954 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2014 | 2119 | 0.010 |
Why?
|
| Beer | 1 | 2003 | 127 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2003 | 319 | 0.010 |
Why?
|
| Bradykinin | 1 | 2003 | 214 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2012 | 3749 | 0.010 |
Why?
|
| Mycobacterium bovis | 1 | 2003 | 150 | 0.010 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2003 | 204 | 0.010 |
Why?
|
| Glycolipids | 1 | 2003 | 204 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2003 | 134 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2011 | 3205 | 0.010 |
Why?
|
| Gene Library | 1 | 2005 | 1074 | 0.010 |
Why?
|
| Membrane Transport Proteins | 1 | 2008 | 1030 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2002 | 19 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2003 | 719 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 424 | 0.010 |
Why?
|
| Selectins | 1 | 2002 | 102 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2008 | 1606 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 2002 | 156 | 0.010 |
Why?
|
| Health Surveys | 1 | 2012 | 4036 | 0.010 |
Why?
|
| Motor Activity | 1 | 2012 | 2714 | 0.010 |
Why?
|
| Colorimetry | 1 | 2002 | 147 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 2050 | 0.010 |
Why?
|
| Sciatic Nerve | 1 | 2005 | 607 | 0.010 |
Why?
|
| Plant Oils | 1 | 2002 | 202 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 12259 | 0.010 |
Why?
|
| Observer Variation | 1 | 2007 | 2592 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2002 | 769 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 5136 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 2002 | 454 | 0.010 |
Why?
|
| Granuloma | 1 | 2003 | 319 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 2861 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2002 | 622 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 13980 | 0.010 |
Why?
|
| Health Status Disparities | 1 | 2012 | 1796 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 11360 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2003 | 1105 | 0.010 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2002 | 315 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2002 | 936 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 1454 | 0.010 |
Why?
|
| Genome, Human | 1 | 2012 | 4418 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2010 | 2683 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 3850 | 0.010 |
Why?
|
| Femoral Artery | 1 | 2003 | 845 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 7719 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2002 | 1588 | 0.010 |
Why?
|
| Species Specificity | 1 | 2002 | 2480 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 999 | 0.010 |
Why?
|
| Lasers | 1 | 2002 | 949 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 2692 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2002 | 2008 | 0.010 |
Why?
|
| Apoptosis | 1 | 2014 | 9718 | 0.010 |
Why?
|
| Cell Separation | 1 | 2002 | 1750 | 0.010 |
Why?
|
| Leptin | 1 | 2005 | 1600 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2369 | 0.010 |
Why?
|
| Exons | 1 | 2002 | 2438 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 3249 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2012 | 11478 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2005 | 3492 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 2914 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2002 | 2749 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 6380 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2002 | 1400 | 0.010 |
Why?
|
| Pregnancy | 1 | 2015 | 29140 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2002 | 4026 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 9648 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2003 | 6441 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2002 | 8939 | 0.000 |
Why?
|
| Lung | 1 | 2003 | 9858 | 0.000 |
Why?
|